#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more
“Use the correct terminology with everything.” –Tom Dayspring
#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring
#20 – Tom Dayspring, M.D., FACP, FNLA – Part I of V: an introduction to lipidology
“Illustrating things made me understand . . . I just learned by illustrating.” –Tom Dayspring
Transcript — The Drive — Dave Feldman
Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.
#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation
“If you learn nothing else today, the first thing is, lipids, for the most part, go nowhere in the human body unless they’re a passenger inside a lipoprotein.” –Tom Dayspring
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#19 – Dave Feldman: stress testing the lipid energy model
“I am on a journey of science, not of advocacy: I’m going to be quite a skeptic.” —Dave Feldman
#26 – AMA #3: supplements, women’s health, patient care, and more
“In case you haven’t guessed yet, there’s been a lot of drug traffic on the beach. And I’m not talking about Robitussin and No-Doze. I’m talking about the hard stuff, and a lot of it. I’ve been trying to find out who’s behind it. It hasn’t been easy. I don’t shower much.” —Irwin M. Fletcher
#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.
“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader